StockNow
CalendarLog in
Global Markets

Novo Nordisk (NOVOB DC) announced first results from the STEP Young phase 3 trial; The trial met its primary endpoint, demonstrating superior body mass index reduction at week 68

StockNow breaking-news AI analysis

Novo Nordisk reported initial STEP Young phase 3 trial results, successfully meeting its primary endpoint with superior body mass index reduction at week 68.

1 stocks
NVONovo-Nordisk A/S$46.53Close

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Politics

Iranian Foreign Ministry spokesperson says the deal with Oman regarding the Strait of Hormuz will be registered soon. Hope parties will not prevent the implementation of the understanding. Qatar's delegation was present within Iran on Sunday.

Commodities

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed

FX/Bonds

[MARKET UPDATE] USD/JPY falls below 155.00 as energy prices weigh on yields in recent trade, down to 154.60 at worst vs 155.55 at 09:00BST